Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print September 9, 2008, 10.1148/radiol.2492071147
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2492071147v1
249/2/471    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Makkat, S.
Right arrow Articles by De Mey, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Makkat, S.
Right arrow Articles by De Mey, J.
(Radiology 2008;249:471-482.)
© RSNA, 2008


Breast Imaging

Deconvolution-based Dynamic Contrast-enhanced MR Imaging of Breast Tumors: Correlation of Tumor Blood Flow with Human Epidermal Growth Factor Receptor 2 Status and Clinicopathologic Findings—Preliminary Results1

Smitha Makkat, MBBS, PhD, Robert Luypaert, PhD, Tadeusz Stadnik, MD, PhD, Claire Bourgain, MD, PhD, Steven Sourbron, PhD, Martine Dujardin, MD, Jacques De Greve, MD, PhD, and Johan De Mey, MD, PhD

1 From the Departments of Radiology (S.M., R.L., T.S., M.D., J.D.M.), Anatomopathology (C.B.), and Medical Oncology (J.D.G.), UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium; and Institute of Clinical Radiology, University Munich-Grosshadern Hospital, Munich, Germany (S.S.). Received June 30, 2007; revision requested August 30; revision received January 31, 2008; accepted March 25; final version accepted June 5. Address correspondence to S.M. (e-mail: Smitha.Makkat{at}vub.ac.be).

Purpose: To prospectively determine whether breast carcinomas possess characteristic values of tumor blood flow (TBF) that correlate with pathologic and molecular prognostic markers.

Materials and Methods: The institutional ethics committee approved this study. After informed consent was obtained, 57 women (age range, 31–80 years) with histologically proved breast cancer underwent routine magnetic resonance (MR) mammography, which included a whole-breast dynamic contrast material–enhanced (DCE) sequence. A second contrast material bolus was injected during dynamic single-section turbo field-echo imaging of the section where the lesion was maximally enhanced. The relative signal intensity changes were deconvolved in a pixelwise fashion to yield the TBF. Formalin-fixed paraffin-embedded tumor specimens on slides were evaluated for histologic size and grade, as well as for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein. In patients with a HER2 protein score of 2+ or 3+, HER2 gene status was assessed. For all prognostic parameters, the Mann-Whitney U test was used to compare median TBF in the HER2-positive group with that in the HER2-negative group.

Results: Significantly higher TBF was observed in tumors larger than 2 cm in diameter and in PR-negative and HER2 gene–amplified tumors (P < .05). In the HER2-positive and HER2-negative groups, ER-positive PR-positive tumors had a lower median TBF than did ER-negative PR-negative tumors, and the difference was significant in the HER2-positive group (P < .05).

Conclusion: Pixelwise deconvolution analysis of DCE MR data in patients with breast cancer can provide preoperative information regarding TBF. These results also support the hypothesis that there is increased TBF in HER2-positive tumors.

© RSNA, 2008







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2008 by the Radiological Society of North America.